Raltegravir: all 174 studies that test it
Page 2 of 2. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).CompletedNCT01978782Phase 1
- Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to RaltegravirTerminatedNCT01902186Phase 4
- A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)CompletedNCT01900106Phase 3
- Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV CoinfectionCompletedNCT01900015Phase 4
- Raltegravir for HAM/TSPCompletedNCT01867320Early Phase 1
- RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected PatientsStatus unknownNCT01829802Phase 4
- Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral TherapyCompletedNCT01825031Phase 3
- Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.CompletedNCT01779687Phase 1
- A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV InfectionStatus unknownNCT01697046Phase 3
- Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir StudyCompletedNCT01679964Phase 4
- Trial to Assess Effect of Raltegravir on HTLV-1 Proviral LoadWithdrawnNCT01620736Phase 2
- Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)CompletedNCT01576731Phase 4
- A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy VolunteersCompletedNCT01531647Phase 1
- Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease InhibitorsCompletedNCT01480713Phase 3
- RAltegravir Switch STudy: Effects on Endothelial RecoveryStatus unknownNCT01453933Phase 4
- Renal Transplantation and Raltegravir in HIV-Infected PatientsCompletedNCT01453192Phase 3
- The Effect of Intermittent Rifampicin on RaltegravirCompletedNCT01424826Phase 1
- Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected PatientsStatus unknownNCT01318096Not applicable
- Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic CirrhosisCompletedNCT01289951Phase 1
- TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and RaltegravirCompletedNCT01288755Phase 1
- Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and NeckCompletedNCT01275183Early Phase 1
- Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.CompletedNCT01258439Phase 4
- TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and RaltegravirCompletedNCT01241773Phase 1
- Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infectionCompletedNCT01231685Phase 2
- Safety Study of Raltegravir in HIV/HCV Co-infected PatientsWithdrawnNCT01225705Phase 4
- Measurement of Plasma and Intracellular Concentrations of RaltegravirCompletedNCT01214486Not applicable
- Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese PatientsStatus unknownNCT01201239Phase 4
- A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear CellsWithdrawnNCT01173510Phase 4
- Pilot Study of Raltegravir Lipodystrophy IISPStatus unknownNCT01164605Not applicable
- Pharmacokinetics of Low Dose RaltegravirCompletedNCT01159132Phase 2
- Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once DailyCompletedNCT01121809Phase 4
- Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV InfectionCompletedNCT01114425Phase 3
- Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug UsersStatus unknownNCT01105611Phase 4
- A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult SubjectsCompletedNCT01101893Phase 1
- Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With MenCompletedNCT01087840Phase 4
- Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected PatientsCompletedNCT01059422Phase 4
- Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected SubjectsCompletedNCT01047995Phase 1
- A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone MaintenanceStatus unknownNCT01042652Not applicable
- Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)CompletedNCT01033760Phase 3
- Raltegravir in Patients With End Stage Liver Disease and in Transplant RecipientsCompletedNCT01022476Phase 1/2
- Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected PatientsStatus unknownNCT01013987Phase 4
- Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIVCompletedNCT00995241Phase 4
- Europe-Africa Research Network for Evaluation of Second-line TherapyCompletedNCT00988039Phase 3
- Effect of Antacids on the Pharmacokinetics of RaltegravirCompletedNCT00944307Phase 1
- Simplification From Protease Inhibitors to RaltegravirStatus unknownNCT00941083Phase 4
- IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected PatientsCompletedNCT00935480Phase 3
- Raltegravir and Atazanavir Dosing Strategy StudyCompletedNCT00874523Phase 3
- Raltegravir Activity In Lymphoid TissuesWithdrawnNCT00863668Not applicable
- Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active TuberculosisCompletedNCT00822315Phase 2
- The Effect of Rifapentine on RaltegravirCompletedNCT00809718Phase 1
- Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 GenotypeCompletedNCT00808184Phase 4
- Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1CompletedNCT00807443Phase 2
- Drug Interaction Study Between Raltegravir And UK-453,061CompletedNCT00784420Phase 1
- Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1TerminatedNCT00781287Phase 4
- Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed ProductCompletedNCT00773708Phase 4
- Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy VolunteersStatus unknownNCT00772720Phase 1
- Raltegravir and Ezetimibe PK StudyCompletedNCT00772551Phase 1
- Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected PatientsCompletedNCT00752037Phase 4
- Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current TreatmentStatus unknownNCT00751153Phase 4
- Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.CompletedNCT00746499Phase 1
- Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected SubjectsStatus unknownNCT00740064Phase 4
- Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART RegimenCompletedNCT00738569Not applicable
- HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in SpainCompletedNCT00685191Phase 4
- Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive PatientsCompletedNCT00677300Phase 4
- Raltegravir as Early Therapy in African-Americans Living With HIV StudyCompletedNCT00667433Phase 1
- The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)CompletedNCT00665717Phase 1
- Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)CompletedNCT00660972Phase 1
- Pharmacokinetic Study on Raltegravir and LamotrigineCompletedNCT00618241Phase 1
- Raltegravir Kaletra PharmacokineticsCompletedNCT00564772Phase 4
- Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 RecoveryTerminatedNCT00562510Phase 3
- Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral SuppressionCompletedNCT00554398Phase 3
- Switching From PI to RALtegravir in HIV Stable PatientsCompletedNCT00528892Phase 3
- Integrase Inhibitor (MK-0518) Viral DecayCompletedNCT00520897Phase 2
- DDI HV (ATV - Merck)CompletedNCT00518297Phase 1